SciSparc Enters Into Non-Binding Letter of Intent to Sell a 50% interest in its Subsidiary that Owns an Amazon Top Seller BrandGlobeNewsWire • 12/14/22
SciSparc Announces Positive Study Results with SCI-210, a Cannabidiol-Based Treatment for EpilepsyGlobeNewsWire • 12/07/22
SciSparc Enters Into Letter of Intent with an E-commerce Company to Establish a Joint Venture to Market and Develop a New Product LineGlobeNewsWire • 11/15/22
SciSparc Announced Positive Interim Results Meeting Primary Endpoints at Phase IIa Study in Alzheimer's Disease Patients with AgitationGlobeNewsWire • 11/07/22
SciSparc Completes the Acquisition of Wellution™, Top Seller of American Food Supplements and Cosmetics Brand on Amazon, for $20 millionGlobeNewsWire • 09/30/22
SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Yields 3rd Patent Application for the Treating of Obesity and Metabolic SyndromesGlobeNewsWire • 09/22/22
SciSparc Enters Agreement to Acquire Wellution™, Top Seller of American Food Supplements and Cosmetics Brand on Amazon, for $20 millionGlobeNewsWire • 09/14/22
SciSparc Ltd. Announces Additional Positive Results for the Cocaine Addiction Treatment of its Psychedelic-based Pharma Collaboration with Clearmind Medicine Inc.GlobeNewsWire • 08/24/22
SciSparc will Deposit $1 million in Escrow for its Intention to Enter Into an Agreement to Acquire American Food Supplements and Cosmetics BrandGlobeNewsWire • 08/18/22
SciSparc Signs a Non- Binding Letter of Intent to Acquire American Food Supplements and Cosmetics Brand in Approximately $20 Million DealGlobeNewsWire • 08/15/22
SciSparc Issued Israeli Patent for its Core Technology for Treating Central Nervous Systems DisordersGlobeNewsWire • 08/12/22
SciSparc Announces Israeli Ministry of Health Approval to Conduct its Clinical Trial in Autism Spectrum DisorderGlobeNewsWire • 08/08/22
SciSparc Signs Clinical Trial Agreement with Yale University to Conduct its Phase IIb Trial in Tourette SyndromeGlobeNewsWire • 08/01/22
SciSparc Announces Expanding its Clinical Operations to Include a U.S. Site Towards its Phase IIb Trial with its Proprietary SCI-110 for the Treatment of Tourette SyndromeGlobeNewsWire • 07/08/22
Traders News Source Interviews Oz Adler Chief Executive Officer at SciSparc Ltd.Accesswire • 07/07/22
SciSparc Successfully Completed The Development of its Proprietary Drug Candidate SCI-110 for its Upcoming Phase IIb Study In Tourette SyndromeGlobeNewsWire • 06/29/22
SciSparc Announces Ethics Committee Approval to Conduct its Clinical Trial in Autism Spectrum DisorderGlobeNewsWire • 06/23/22
SciSparc Reinforces its New JV for Targeting Discovery with a Global Expert in the Field of Mitochondrial Transport ProteinsGlobeNewsWire • 06/15/22